Key Takeaway
Should you ask your provider about semaglutide or tirzepatide? A GLP-1 medication comparison tool puts the key differences side by side so you can walk into your consultation informed and ready with the right questions. Both medications work. Both have strong clinical evidence.
Should you ask your provider about semaglutide or tirzepatide? A GLP-1 medication comparison tool puts the key differences side by side so you can walk into your consultation informed and ready with the right questions. Both medications work. Both have strong clinical evidence. But they're not identical.
Key Takeaways: - Learn how semaglutide and tirzepatide work differently - Side-by-Side Comparison Chart - Comparing Side Effects - Factors to Discuss With Your Provider - Learn how to use this comparison to prepare for your appointment
This guide compares the two most popular GLP-1 medications across every factor that matters (mechanism, dosing, results, side effects, and cost.
How Semaglutide and Tirzepatide Work Differently
Both medications belong to the GLP-1 class, but their mechanisms have a key difference.
Semaglutide is a GLP-1 receptor agonist. It mimics the natural GLP-1 hormone your body produces after eating. This hormone signals your brain to feel full, slows stomach emptying, and helps regulate blood sugar. Semaglutide activates one receptor.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates two receptors) both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone that plays a role in fat metabolism, insulin secretion, and appetite regulation. This dual action may explain why tirzepatide showed slightly greater weight loss in clinical trials.
Think of it this way: semaglutide turns one dial. Tirzepatide turns two.
Both are administered as once-weekly subcutaneous injections. Both follow a gradual titration schedule where you start at a low dose and increase over time.
For a deeper look at each medication individually, check out our and .
"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.", Dr. Caroline Apovian, MD, Harvard Medical School
Side-by-Side Comparison Chart
Here's how the two medications stack up across key factors:
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Frequency | Once weekly | Once weekly |
| Starting dose | 0.25 mg | 2.5 mg |
| Maximum dose | 2.4 mg | 15 mg |
| Titration period | ~16-20 weeks | ~20-24 weeks |
| Avg. Weight loss | ~15% body weight | ~15-22% body weight |
| Common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea, constipation |
| Injection route | Subcutaneous | Subcutaneous |
Free Download: Universal Peptide Dose Conversion Table Print this reference alongside your GLP-1 comparison chart. Covers dose conversions for semaglutide, tirzepatide, and common peptides. Get yours free (we'll email it to you instantly.
[Download CTA Button]
Important note: The weight loss percentages come from separate clinical trials with different study populations. Direct head-to-head comparison data is limited. Your individual response to each medication may differ from the averages.
Comparing Side Effects
The side effect profiles are similar but not identical. Both medications share the most common side effects because they both activate GLP-1 receptors.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Shared side effects (most common): - Nausea (especially during dose increases) - Vomiting - Diarrhea - Constipation - Decreased appetite (this is also the therapeutic effect) - Injection site reactions
Frequency comparison: In clinical trials, gastrointestinal side effects occurred in roughly 40-50% of participants for both medications. But the majority were mild to moderate and decreased over time. Most side effects peak during dose escalation and improve once your body adjusts.
How to manage side effects: Our covers practical strategies for handling nausea, constipation, and other common issues. Small meals, adequate hydration, and eating slowly can make a significant difference.
If you're experiencing side effects that don't improve, your provider may recommend slowing your titration schedule, adjusting your dose, or switching medications. This is one advantage of working with a platform like ) your provider can adjust your treatment plan based on your response.
Factors to Discuss With Your Provider
The "best" GLP-1 medication depends on your individual situation. Here are factors worth discussing during your consultation.
Your health history. Certain conditions may make one medication more appropriate than the other. For example, if you have type 2 diabetes, both medications are effective for blood sugar management, but your provider may have a preference based on your specific metabolic profile.
Your weight loss goals. If you have a significant amount of weight to lose, the potentially greater average weight loss with tirzepatide may factor into the decision. But remember (individual responses vary widely.
Your tolerance for side effects. If you're concerned about gastrointestinal side effects, your provider may start with the medication that has the slower titration to minimize initial discomfort.
Cost and access. Compounded versions of both medications are available through at transparent pricing. Check our for current rates.
Previous experience. If you've tried one medication and didn't respond well, switching to the other is a reasonable conversation to have with your provider.
You can use our to get started with a provider evaluation. The quiz collects your health information so your provider can make an informed recommendation.
How to Use This Comparison to Prepare for Your Appointment
Don't just show up and ask "which one is better?" Instead, use this comparison to ask targeted questions.
Ask: "Based on my health history, which mechanism) single or dual receptor (do you think would be more beneficial for me?"
Ask: "Given my weight loss goals, what's a realistic timeline with each medication?"
Ask: "What's your approach if I experience side effects that don't resolve during titration?"
Ask: "If I start with one and it doesn't work well, can we switch to the other?"
Coming prepared with specific questions shows your provider that you've done your homework. It also leads to more productive appointments.
The lets you track your progress on whichever medication your provider recommends. You can log doses, weight, side effects, and other metrics to share during follow-up appointments.
Frequently Asked Questions
Can I switch from semaglutide to tirzepatide or vice versa?
Yes, switching is possible under provider guidance. Your provider will determine the appropriate starting dose of the new medication and create a new titration schedule. There's typically no washout period needed) you can transition directly. Discuss the timing and approach with your provider.
Is tirzepatide always better than semaglutide for weight loss?
Not necessarily. Clinical trial averages favor tirzepatide at higher doses, but individual responses vary. Some people respond better to semaglutide. The best medication for you depends on your unique biology, health conditions, and tolerance. Your provider helps determine the right choice.
Do both medications require a prescription?
Yes. Both semaglutide and tirzepatide are prescription medications that require evaluation by a licensed healthcare provider. FormBlends connects you with providers who can evaluate your eligibility and prescribe the appropriate medication based on your health profile.
Can I take both medications at the same time?
No. Semaglutide and tirzepatide shouldn't be taken simultaneously. They activate overlapping receptors, and combining them would increase the risk of side effects without established safety data. Your provider will prescribe one or the other.
Let's Make This Happen
The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide (no pressure, no commitment.
Medical References
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
This article is for educational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →